Tandem Diabetes Care (TNDM) Q2 2025: Pharmacy Channel Expands to 30% Coverage, Margin Path to 60% Affirmed
Tandem’s Q2 spotlighted a multi-channel transformation, with pharmacy coverage reaching 30% of U.S. lives and direct OUS expansion driving upside. Strategic execution on product innovation and operational leverage is supporting a clear path to margin expansion, as the company eyes $1B in sales and a quarterly 60% gross margin exit in 2026. Investors now face a recalibrated U.S. growth outlook, but international and channel mix shifts are unlocking new profitability levers.
Summary
- Pharmacy Channel Acceleration: 30% U.S. coverage achieved, with supplies launching in Q4 to boost access and profit.
- International Direct Model: Direct sales transition reduces headwinds, with renewals emerging as a new OUS growth vector.
- Margin Expansion Path: Mobi cost improvements and channel mix underpin confidence in achieving 60% gross margin by 2026 exit.
Performance Analysis
Tandem delivered record second quarter sales in both the U.S. and international markets, driven by continued pump adoption, double-digit renewal growth, and early pharmacy channel traction. U.S. sales growth reflected strong retention, with renewals now accounting for just over half of domestic pump shipments. Mobi, the company’s modular pump platform, continued to gain share among new users, while T-Slim X2 remained a preferred choice for its higher-volume reservoir and touchscreen control.
International sales outperformed expectations despite distributor inventory adjustments ahead of the 2026 direct sales transition. Renewals and supply sales are now contributing more meaningfully outside the U.S., marking a shift from the prior focus on new market development. Gross margin improvement was a standout, expanding to 52% on pricing, operational leverage, and early Mobi cost reductions. Pharmacy channel volumes, though still small, delivered incremental revenue and margin benefits, and are poised to scale as T-Slim supplies enter the channel in Q4.
- Renewals as Growth Engine: U.S. renewals grew double digits and now exceed 50% of pump shipments, supporting recurring revenue stability.
- Pharmacy Channel Premium: Pricing in pharmacy exceeds DME, driving higher profit per unit as coverage expands.
- International Leverage: Direct sales transition reduces distributor headwinds and unlocks margin upside in 2026.
With 75% of U.S. sales now recurring (renewals and supplies), Tandem’s model is tilting toward predictability. However, new pump starts are expected to be flat to slightly down, reflecting both competitive intensity and the timing of commercial transformation benefits.
Executive Commentary
"We achieved record second quarter sales, both in the US and internationally. We've strengthened our business model by progressing our multi-channel market access strategy, including accelerating our pharmacy channel initiative. In addition, we made meaningful progress in transforming key business systems to improve our commercial teams effectiveness and increase profit margins."
John Sheridan, President and Chief Executive Officer
"Our entry into the pharmacy channel was predicated on two objectives, to lower out-of-pocket costs for our patients and to drive sales and margins more in line with industry comps. We are still in the early stages, but are already seeing examples of patients paying zero up front, out of pocket under our current agreements."
Lee Vossler, Executive Vice President and Chief Financial Officer
Strategic Positioning
1. Multi-Channel Market Access
Tandem’s pivot to a multi-channel approach—combining DME (Durable Medical Equipment, traditional insurance channel) and pharmacy—has become a strategic differentiator. Pharmacy channel coverage reached 30% of U.S. lives, with additional contracts imminent. The Q4 launch of T-Slim supplies in pharmacy is expected to accelerate adoption and improve affordability, while also delivering premium pricing and margin lift compared to DME.
2. Product Innovation and Pipeline
Product leadership remains central, with Mobi’s modular design and upcoming Android control broadening its appeal. The integration of extended wear technology into both infusion sets (SteadySet) and the tubeless Mobi design aims to enhance user experience and reduce insulin waste, especially for type 2 patients. The pipeline includes a fully closed loop system and further sensor integrations, reinforcing Tandem’s technology ecosystem.
3. International Direct Expansion
Transitioning to direct sales in key international markets is reducing distributor-related headwinds and unlocking new margin opportunities. Early signs of renewal traction outside the U.S. suggest recurring revenue streams are taking hold, supporting more predictable growth as the company globalizes its commercial footprint.
4. Type 2 Diabetes Market Entry
The type 2 diabetes segment represents a major expansion opportunity, effectively doubling the addressable market. Pilot programs in select territories have outperformed non-pilot areas, validating the approach and informing broader rollout. Pending CMS reimbursement changes and ongoing Medicare advocacy could further accelerate adoption among insulin-intensive type 2 patients.
5. Operational Efficiency and Cost Control
Operating expense growth was contained despite investments in sales force and technology modernization. R&D spend was flat year-over-year, reflecting improved efficiency in innovation delivery. The company expects SG&A investment to be offset by future savings, supporting the margin expansion thesis.
Key Considerations
This quarter underscored Tandem’s ability to execute on channel and geographic diversification, while also highlighting the timing risks inherent in large-scale commercial transformation. Investors should focus on the company’s evolving revenue mix, margin trajectory, and the scalability of its pharmacy and international initiatives.
Key Considerations:
- Pharmacy Channel Ramp: Early results are promising, but the pace of coverage expansion and patient adoption will determine the channel’s true impact on growth and profitability.
- International Direct Model: The headwind from distributor de-stocking is lower than forecast, suggesting upside as direct sales and renewals scale in 2026 and beyond.
- Competitive Environment: New U.S. market entrants and aggressive competitor salesforces are causing some near-term pausing among prescribers and patients, impacting new pump starts.
- Recurring Revenue Stability: With renewals and supplies now 75% of U.S. sales, the business model is more resilient, but flat renewal opportunity in 2026 will require new user growth or channel expansion to sustain double-digit growth.
- Product Pipeline Execution: Timely launches and regulatory wins for SteadySet and tubeless Mobi will be critical to maintaining product leadership and margin targets.
Risks
Competitive intensity in the U.S. is rising, with new entrants expanding salesforces and potentially disrupting prescriber behavior. The timing of commercial system upgrades and salesforce productivity improvements remains a risk to near-term U.S. growth. Regulatory changes, particularly around Medicare reimbursement and competitive bidding, could alter channel economics, though current exposure is limited. Execution risk around pharmacy channel ramp and international direct transition could impact both top-line and margin guidance if not managed tightly.
Forward Outlook
For Q3 2025, Tandem guided to:
- Worldwide revenue of approximately $235 million, a slight sequential step down from Q2 due to modest Q2 stocking and currency benefits.
- Gross margin expansion as Mobi volumes and pharmacy channel mix increase through the year.
For full-year 2025, management raised worldwide sales guidance to $1 billion, split $700 million U.S. and $300 million international. Gross margin guidance is 53 to 54%, with a clear path to 60% by Q4 2026. Adjusted EBITDA guidance was recast to negative 5% due to a one-time IPR&D charge, but operational margin improvement is expected to materialize in the second half and accelerate in 2026.
Management highlighted:
- Further pharmacy channel expansion and T-Slim supplies launch in Q4 as key levers for growth and margin.
- Direct OUS transition and renewal ramp as incremental drivers for 2026.
Takeaways
Tandem’s Q2 marked a strategic inflection, with multi-channel expansion and international direct sales setting up a more diversified, margin-rich model. Investors should monitor the pace of pharmacy channel penetration and execution on operational upgrades as leading indicators of sustainable double-digit growth and margin attainment.
- Margin Expansion Commitment: Mobi cost reductions and pharmacy channel mix are translating to tangible gross margin gains, supporting the 60% exit target for 2026.
- Revenue Mix Evolution: Recurring revenue now dominates, but new user growth—especially via pharmacy and type 2—will be needed to offset flat renewals in 2026.
- Execution Watchpoint: Timely product launches, commercial transformation, and competitor response will define the next phase of Tandem’s growth story.
Conclusion
Tandem’s Q2 showcased disciplined execution on channel, product, and operational initiatives, positioning the company for profitable growth despite a recalibrated U.S. outlook. The next 12 months will test the scalability of its pharmacy and international strategies, with margin expansion and new market penetration as the primary investor watchpoints.
Industry Read-Through
Tandem’s aggressive pharmacy channel expansion and direct OUS transition signal a broader industry shift toward multi-channel access and recurring revenue models in medtech. Competitors reliant on DME or indirect distribution may face margin and growth pressure as payers and patients demand greater affordability and access. The focus on type 2 diabetes and extended wear technology highlights the increasing importance of product flexibility and patient-centric solutions in driving adoption. Investors should watch for similar channel and product moves across the diabetes device sector as the competitive landscape evolves.